We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Mini-Transplants of Stem Cells for Older Patients

By HospiMedica staff writers
Posted on 06 Jun 2001
A study has found that low-dose radiation therapy combined with immunosuppressive drugs allows donor stem-cell transplants in patients who cannot have conventional stem-cell transplants, such as people over 50 years of age with leukemia or some other potentially fatal blood cancer. More...
The study, conducted by researchers at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) and four other centers, was published in the June 1, 2001, issue of Circulation.

The toxic effects of conventional stem-cell transplants are a major problem for older patients as well as young patients. The study involved 45 patients diagnosed with acute and chronic leukemia, multiple myeloma, non-Hodgkin's lymphoma, and other diseases. The researchers used non-myeloablative stem-cell transplants, also known as mini-transplants. The mini-transplant procedure involved very low doses of radiation, coupled with post-transplant immune suppression, to establish a stable state of tolerance between donor cells and the patient's own tissues, a phenomenon called "mixed hematopoietic chimerism.”

Few of the patients required hospitalization and most experienced only mild to moderate treatment-related toxicities. Patients did not lose their hair. Eight patients with chronic leukemia entered a complete molecular remission. Survival rate among the patients was 66%. To date, more than 300 patients have been treated with this procedure. The researchers attribute the positive responses to graft-versus-tumor effect and the use of post-engraftment immunosuppression.

"The revolutionary part of the whole concept is that the cancer is eliminated through the donor T-cells rather than with high-dose chemo-radiation therapy,” said Dr. Rainer Storb, senior investigator of the study and professor of medicine at the University of Washington (Seattle, USA).




Related Links:
Fred Hutchinson Cancer Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.